Frazier Life Sciences Management L.P. Purchases New Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Frazier Life Sciences Management L.P. acquired a new position in Immunocore Holdings plc (NASDAQ:IMCR) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 108,762 shares of the company’s stock, valued at approximately $3,686,000. Frazier Life Sciences Management L.P. owned 0.22% of Immunocore at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. NEOS Investment Management LLC acquired a new stake in Immunocore during the fourth quarter worth $262,000. Tidal Investments LLC bought a new stake in Immunocore in the first quarter valued at about $423,000. China Universal Asset Management Co. Ltd. raised its position in Immunocore by 69.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock worth $430,000 after purchasing an additional 2,721 shares in the last quarter. Nan Fung Group Holdings Ltd acquired a new stake in Immunocore during the first quarter valued at approximately $439,000. Finally, DNB Asset Management AS boosted its holdings in Immunocore by 35.0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after purchasing an additional 1,868 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Stock Performance

IMCR stock opened at $31.40 on Friday. The company has a 50 day moving average price of $35.94 and a 200 day moving average price of $45.28. Immunocore Holdings plc has a fifty-two week low of $29.76 and a fifty-two week high of $76.98. The company has a debt-to-equity ratio of 1.31, a current ratio of 5.17 and a quick ratio of 5.15. The stock has a market capitalization of $1.57 billion, a PE ratio of -25.74 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.25. The business had revenue of $75.40 million for the quarter, compared to analyst estimates of $74.58 million. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The firm’s revenue for the quarter was up 26.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.37) earnings per share. Analysts forecast that Immunocore Holdings plc will post -1.79 EPS for the current year.

Analyst Ratings Changes

IMCR has been the subject of several analyst reports. Oppenheimer restated an “outperform” rating and set a $89.00 target price (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a report on Monday, September 9th. Needham & Company LLC dropped their target price on shares of Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a research report on Tuesday, September 17th. Barclays reduced their price target on shares of Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Immunocore from $70.00 to $66.00 and set an “overweight” rating for the company in a report on Wednesday, July 10th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $80.40.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.